

^d Área Académica de Ciencias Ambientales, Universidad Autónoma del Estado de Hidalgo, Pachuca, Hidalgo, Mexico

* Corresponding author.

E-mail addresses: prietog@uaeh.edu.mx,
prietogmx@yahoo.com.mx (F. Prieto García).

2013-2514/© 2015 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>).
<http://dx.doi.org/10.1016/j.nefro.2015.02.006>

Letter to the Editor – Brief Case Reports

The evolution of occult Hepatitis C Virus after immunosuppression in advanced CKD patients[☆]

Evolución del virus de la hepatitis C oculto tras inmunosupresión en enfermedad renal crónica avanzada

To the Editor,

Hepatitis C Virus (HCV) affects prognosis in patients with advanced chronic kidney disease (ACKD). A high prevalence of classic and occult HCV has been described in the haemodialysis population.^{1,2} Although we are in a new era of antiviral treatment, there are no studies supporting the indication of this therapy in patients with occult HCV infection yet. The ACKD population that is to receive future immunosuppression appears to be at risk for viral replication. Therefore, it would bear considering pre-immunosuppression antiviral treatment.³ There is just 1 published case on the subject, although that patient did not have renal disease.⁴ This letter presents the clinical course of occult HCV in 2 patients with ACKD who received immunosuppressive therapy. The determination of occult HCV was performed in *la Fundación para el Estudio de las Hepatitis Virales* (the Foundation for the Study of Viral Hepatides), using ultracentrifugation of serum⁵ and ultrasensitive PCR in the liver and in peripheral blood mononuclear cells (PBMC).⁶ In recent years, the high-sensitivity anti-HCV core antibody detection technique has been added.⁷

Case 1

A 40-year-old woman, smoker, with systemic lupus erythematosus, antiphospholipid syndrome, hypertension, tertiary hyperparathyroidism, osteoporosis, hyperhomocysteinaemia,

and hyperuricaemia. She began haemodialysis in 1990 (renal transplant from 1991 to 1998). Regular medications were cinacalcet, aluminium hydroxide, calcium acetate, risendronate, folic acid, multivitamin B1/B6/B12, omeprazole, allopurinol, carvedilol, hydroxychloroquine, acenocoumarol, iron, and intradialytic darbopoetin.

From March 2008, serial “indeterminate” results were ascertained (ELISA, RIMA) for HCV (positive only for the NS3 fraction). Several retests were carried out, and cross-reaction testing was performed for underlying autoimmune disease. Despite normal blood transaminase levels, the possibility was raised of occult HCV. This was confirmed in peripheral blood mononuclear cells (PBMC, 1170 copies/ μ g total RNA), and in the liver. Further investigations were performed: transjugular liver biopsy, showing chronic hepatitis grade/stage 0/0; FibroScan[®], 6.3 KPa; APRI, 0.81; and Forns score, 7.59. Potential external contamination was tested for, but did not occur: viral PCR and serology were performed on the other patients in the unit and the healthcare staff. No new cases of classic HCV infection were detected. In February 2009, the patient received intravenous immunoglobulin IVIG (2 g/kg) for pre-transplant desensitisation (in the end, transplant was not performed, for other reasons), and from June to November 2009 she received azathioprine (AZT 50 mg/day) and corticoid therapy (GC 5 mg/day) for lupus activity. There was no observed increase in the intralymphocyte viral load, although there was an immune response (Fig. 1). In March and April 2009, there was a transient mild increase in ALT, with a maximum level of 42 UI/L.

DOI of original article:

<http://dx.doi.org/10.1016/j.nefro.2015.06.005>.

[☆] Please cite this article as: Martín-Gómez MA, Castillo-Aguilar I, Barril-Cuadrado G, Cabezas-Fernández T, Casado-Martín M, Cabello-Díaz M. Evolución del virus de la hepatitis C oculto tras inmunosupresión en enfermedad renal crónica avanzada. *Nefrología*. 2015;35:511–513.




Fig. 1 – Changes in conventional anti-HCV antibodies and occult HCV viral load. Laboratory threshold for positivity for anti-HCN antibodies (HCV Ab), 4 UI. AZT, azathioprine; GC, glucocorticoids; IVIG, intravenous immunoglobulin.

Case 2

A 51-year-old man with ACKD of unknown aetiology and hypertension, who began dialysis in 2005. His first renal

transplant failed immediately due to non-immunological arterial thrombosis in October 2007. During that admission he received 2 units of red blood cells. Transaminases were sporadically raised in 2009, with a sustained increase in December 2010 (maximum level 28/40 UI/L AST/ALT). Occult HCV was




Fig. 2 – Changes in conventional anti-HCV antibodies and occult HCV viral load. Laboratory threshold for positivity for anti-HCN antibodies (HCV Ab), 4 UI. PBMC, peripheral blood mononuclear cells; Dx, diagnosis; FK, tacrolimus; GC, glucocorticoids; MMF, mycophenolate mofetil; TG, thymoglobulin; Tx, transplant.

diagnosed with 14 700 copies/ μg total RNA in PBMC (RNA negative in serum on ultracentrifugation and high-sensitivity anti-HCV core antibody negative). Ultrasound and FibroScan[®] were normal. Potential external contamination was tested for, but did not occur: viral PCR and serology were performed in the other patients in the unit and the healthcare staff. No new cases of classic HCV infection were detected. The patient received a second renal transplant in October 2013 and was treated with thymoglobulin (TG), tacrolimus (FK), mycophenolate (MMF), and corticoids. Seventeen months post-transplant, PBMC viral load was undetectable, and RNA on serum ultracentrifugation and high-sensitivity anti-HCV core antibody both remained negative (Fig. 2).

Discussion

The infectivity⁸ and pathogenicity of occult HCV have been described, but there is still insufficient experience to justify HCV eradication. Currently, only cases in research protocols have been treated.³

There is evidence, though very little, of HCV replicator activity in the presence of immunosuppressive stimuli.⁴ Therefore, in hyperimmunised patients requiring aggressive immunosuppression in the peritransplant period, including long-term corticoid therapy, doubt remains as to whether pre-transplant antiviral therapy should be considered.

This letter presents the second and third cases from the literature of patients with occult HCV who received immunosuppressive therapy. These are the first described cases with ACKD. In the first case presented here, which occurred following AZT, the intralymphocyte viral load did not increase, and even decreased to undetectable levels, whilst the antibody titre increased. This suggests that the patient's immune system, though supposedly weakened, overcame the viraemia. In the second case, the viral load was cleared to negative, but without the production of immune antibodies against the virus (there was an increase in the level of antibodies, but this was transient and did not reach the laboratory threshold).

The observed activity of the immunity/virology relationship cannot be explained based on this experience alone. Quiroga et al.⁹ demonstrated that occult HCV did induce a CD4⁺/CD8⁺ cellular response in immunocompetent patients, but without detection of specific antibodies. However, little is known about HCV activity in immunocompromised patients, particularly when taking into account, the different types and degrees of immunosuppression that exist, including that proportionally related to uraemia.

Conclusion

In conclusion, there is insufficient evidence to justify antiviral treatment in patients with chronic kidney disease and occult HCV, even when immunosuppressive treatment is anticipated. Therefore, we remain expectant and await further results.

REFERENCES

1. Fabrizi F, Martin P, Dixit V, Messa P. Hepatitis C virus infection and kidney disease: a meta-analysis. *Clin J Am Soc Nephrol.* 2012;7:549-57.
2. Barril G, Castillo I, Arenas MD, Espinosa M, García-Valdecasas J, García-Fernández N, et al. Occult hepatitis C virus infection among hemodialysis patients. *J Am Soc Nephrol.* 2008;19:2288-92.
3. Pardo M, López-Alcorocho JM, Castillo I, Rodríguez-Iñigo E, Perez-Mota A, Carreño V. Effect of anti-viral therapy for occult hepatitis C virus infection. *Aliment Pharmacol Ther.* 2006;23:1153-9.
4. Lee WM, Polson JE, Carney DS, Sahin B, Gale M Jr. Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: evidence for an occult viral reservoir. *J Infect Dis.* 2005;192:1088-92.
5. Bartolomé J, López-Alcorocho JM, Castillo I, Rodríguez-Iñigo E, Quiroga JA, Palacios R, et al. Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C. *J Virol.* 2007;81:7710-5.
6. Carreño V, Pardo M, López-Alcorocho JM, Rodríguez-Iñigo E, Bartolomé J, Castillo I. Detection of hepatitis C virus (HCV) RNA in the liver of healthy, anti-HCV antibody-positive, serum HCV RNA-negative patients with normal alanine aminotransferase levels. *J Infect Dis.* 2006;194:53-60.
7. Barril G, Quiroga JA, Arenas D, Espinosa M, García N, Cigarrán S, et al. Impact of isolated hepatitis C virus (HCV) core-specific antibody detection and viral RNA amplification among HCD-seronegative dialysis patients at risk for infection. *J Clin Microbiol.* 2014;52:3053-6.
8. Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Hepatitis C virus infection in the family setting of patients with occult hepatitis C. *J Med Virol.* 2009;81:1198-203.
9. Quiroga JA, Llorente S, Castillo I, Rodríguez-Iñigo E, Pardo M, Carreño V. Cellular immune responses associated with occult hepatitis C virus infection of the liver. *J Virol.* 2006;80:10972-9.

María Adoración Martín-Gómez^{a,*}, Inmaculada Castillo-Aguilar^b,
Guillermina Barril-Cuadrado^c, Teresa Cabezas-Fernández^d,
Marta Casado-Martín^e, Mercedes Cabello-Díaz^f

^a Unidad de Nefrología, Hospital de Poniente, El Ejido, Almería, Spain

^b Laboratorio, Clínica Fundación para el Estudio de las Hepatitis Virales, Madrid, Spain

^c Servicio de Nefrología, Hospital de la Princesa, Madrid, Spain

^d Departamento de Microbiología, Hospital de Poniente, El Ejido, Almería, Spain

^e Unidad de Hepatología, Hospital Torrecárdenas, Almería, Spain

^f Servicio de Nefrología, Hospital Carlos Haya, Málaga, Spain

Corresponding author at: Unidad de Nefrología, Hospital de Poniente, Ctra. Málaga n.º 119, 04700, El Ejido, Almería, Spain. Tel.: +34 677081239.

E-mail address: doritamg@gmail.com (M.A. Martín-Gómez).

2013-2514/© 2015 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).
<http://dx.doi.org/10.1016/j.nefro.2015.11.001>